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The implantation of implantable cardioverter-deﬁbrillator
(ICD) systems in patients with no or limited venous access
is technically challenging. After disappointing experiences
with epicardial ICD patches,1,2 surgical techniques focused
on the implantation of subcutaneous high-voltage array
electrodes or intrapericardial placement of standard trans-
venous ICD leads.3–6 The Boston Scientiﬁc subcutaneous
ICD (Boston Scientiﬁc, Marlborough, MA) is the ﬁrst
completely subcutaneous ICD (S-ICD), initially approved
in Europe in 2009 and market released in the United States in
2012. The S-ICD is an effective and attractive alternative to
transvenous ICD systems in patients without need for
antitachycardia or antibradycardia pacing.7,8 Previous trials
excluded patients with existing epicardial deﬁbrillation
patches or coils, presence of epicardial pacing leads, unipolar
pacemaker systems, or documented monomorphic ventricu-
lar tachycardia likely to be terminated by antitachycardia
pacing.8,9 Therefore the safety and feasibility of S-ICD
systems in patients with a concomitant epicardial pacing
system and a class I indication for antibradycardia pacing is
unknown.
We report a case of a patient with an indication for
both a secondary prevention ICD and permanent pacing
who was high risk for recurrent bacterial seeding of a
transvenous device and who underwent successful implan-
tation of an epicardial pacemaker and a Boston Scientiﬁc
S-ICD system.KEYWORDS ICD; S-ICD; Epicardial pacemaker; Limited venous access; Device
interaction; Recurrent device infection; Sensing screening
ABBREVIATIONS bpm¼ beats per minute; DFT¼ defibrillation threshold;
ICD ¼ implantable cardioverter-defibrillator; MRSA ¼ methicillin-
resistant Staphylococcus aureus; S-ICD ¼ subcutaneous ICD;
VF¼ ventricular fibrillation (Heart Rhythm Case Reports 2015;1:419–423)
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A 78-year-old man presented with recurrent sepsis and
bacteremia caused by methicillin-resistant Staphylococcus
aureus (MRSA). His past medical history was signiﬁcant for
a dual-chamber ICD (Medtronic Protecta XT) implanted 3
years prior for polymorphic ventricular tachycardia with
appropriate shocks during follow-up. The patient also had
complicated type II diabetes with vascular involvement
including chronic bilateral diabetic feet.
Before the patient came to our attention he had experi-
enced 2 years of recurrent episodes of MRSA bacteremia
necessitating prolonged courses of intravenous antibiotics
adding up to a total of 12 months intravenous therapy with
vancomycin and clindamycin. Blood cultures on admission
at our center were again positive for MRSA, with extensive
resistance to antibiotics including vancomycin. The soft
tissues around the ICD pocket were unremarkable. A trans-
esophageal echocardiogram demonstrated a 10 mm vegeta-
tion attached to one of the device leads at the atrial level
without evidence of any direct valvular involvement.
A previously undiagnosed chronic osteomyelitis of the left
great toe was found to be the source for the patient’s
recurrent bacteremia and a number of his other toes had
healing diabetic ulcers. An amputation of the patient’s left
great toe was performed prior to the extraction of his ICD
system. Concomitant antibiotics consisting of intravenous
daptomycin and oral trimethoprim/sulfamethoxazole were
administered over a total of 6 weeks after ICD extraction.
Because of his recurrent intravascular infections and signiﬁ-
cant risk of future bacteremia, we evaluated the option of a total
extravascular pacemaker and ICD system. Antibradycardia pac-
ing was required because of underlying 2:1 atrioventricular block.Procedure
A dual-chamber bipolar epicardial pacemaker system was
implanted using the right atrium and right ventricle via a
right minithoracotomy (Figure 1A). The 2 epicardial
leads (Medtronic 4968 CapSure Epi, 35 cm for atrial
and ventricular lead; Medtronic, Minneapolis, MN) were
subcutaneously tunneled to an epigastric pulse generatorpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.04.001
KEY TEACHING POINTS
 Combination of epicardial pacemaker system and
subcutaneous implantable cardioverter-
deﬁbrillator (S-ICD) is an alternative and safe
device option in patients with limited or absent
venous access.
 Complex interaction between both devices exhibits
potential for double counting and inappropriate
shocks through S-ICD and requires a very careful
sensing screening and programming.
 Close follow-up and frequent check for oversensing
through the S-ICD is mandatory.
Heart Rhythm Case Reports, Vol 1, No 6, November 2015420(ALTRUA; Boston Scientiﬁc, Marlborough, MA). Both atrial
electrodes were placed on the right atrial free wall. One
ventricular electrode was placed on the inferior surface and 1
on the anterior surface of the right ventricle owing to extensive
adipose accumulation on the right ventricle and difﬁculty
ﬁnding adequate muscle to attach the leads (Figure 1B).Figure 1 Chest radiographs before and after implantation of subcutaneous
pacemaker.A: Lateral chest radiograph of the transvenous dual-chamber ICD system
of S-ICD and permanent epicardial pacemaker. The 2 epicardial atrial electrodes
ventricular electrodes of the epicardial pacemaker are ﬁxed to the inferior and anter
the S-ICD is positioned in a subcutaneous pocket at the lower left-lateral thorax (d
(black arrowheads). C: Shown are the 3 bipolar sensing vectors of an S-ICD. The
secondary vector senses between the distal lead electrode and the can. The alternaScreening for S-ICD sensing with a standard left para-
sternal lead position failed because only paced beats but not
intrinsic beats were adequately detected in any vector
conﬁguration. Right parasternal screening showed adequate
sensing parameters for intrinsic and paced beats in the
primary (B to can) and secondary (A to can) vector
conﬁguration. The S-ICD was ﬁnally implanted on the left
side of the thorax and the ICD lead was placed along the right
parasternal border (Figure 1B).
During implantation we observed double counting of the
epicardial atrial pacing through the S-ICD. At higher atrial
pacing output (3.5 V/0.4 ms) the S-ICD detected atrial pacing in
the secondary sensing vector (Figure 2A) but not in the primary
sensing vector (Figure 2C). Lowering of the atrial pacing output
to 1.5 V/0.4 ms eliminated double counting through the S-ICD
(Figure 2B) at nominal sensitivity settings of the S-ICD.
Device settings and testing of deﬁbrillation
threshold
The right ventricular pacing threshold was 1.7 V at 0.5 ms
and the epicardial R-wave amplitude was measured at
3.9 mV through the dual-chamber pacemaker.implantable cardioverter-deﬁbrillator (S-ICD) and permanent epicardial
prior to extraction. B: Posterior-anterior chest radiograph post implantation
are ﬁxed to the free wall of the right atrium (bold white arrows). The 2
ior surface of the right ventricle, respectively (bold black arrows). The can of
ashed white arrow). The S-ICD lead is placed in a right parasternal position
primary vector senses between the proximal lead electrode and the can. The
te vector senses between the 2 lead electrodes.
Figure 2 Sensing ﬁndings at implantation of the subcutaneous implantable cardioverter-deﬁbrillator (S-ICD).A:Higher atrial pacing output (3.5 V/0.4 ms) by
the epicardial pacemaker resulted in detection of atrial pacing and double counting through the S-ICD in the secondary sensing vector, but not in the primary
sensing vector (C). B: Lowering of the atrial pacing output to 1.5 V/0.4 ms eliminated double counting through the S-ICD in the secondary sensing vector.
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were set to 100 beats per minute (bpm) and the trigger rate
for shock delivery through the S-ICD was set to 220 bpm.
The pacing output for the right ventricle and atrium during
deﬁbrillation threshold (DFT) testing was set to 5 V and 3.5
V, respectively.
Ventricular ﬁbrillation (VF) was induced via a 50 Hz
burst. The dual-chamber epicardial pacemaker failed to
detect the 50 Hz burst (Figure 3A), but correctly sensed
the induced VF (Figure 3B). The ﬁrst 3 VF inductions were
successful, but VF terminated spontaneously before the
S-ICD could deliver a shock (Figure 3B). Subsequently VF
was not inducible any longer. All episodes of VF were
appropriately sensed by the S-ICD.Discussion
The S-ICD is now increasingly being implanted worldwide
and clinical experience reveals that the S-ICD system is a
reliable and effective alternative compared to standard trans-
venous ICD systems.8,10 However, there are only limited data
on patients with concomitant transvenous pacemakers sys-
tems.8,11 For example, in the EFFORTLESS registry, only 3%
of all patients had a transvenous pacemaker system in addition
to the S-ICD and none of them had an epicardial pacemaker.
Our report demonstrates the feasibility of the co-
implantation of an S-ICD system with a permanent epicardial
pacemaker, which exhibits several unique and challenging
elements.As mentioned before, a total extravascular device system
was chosen for our patient because of the high risk of
recurrent device infection. Although the rates of pocket
infection in S-ICDs are currently still higher compared to
standard transvenous ICDs, both the mortality and morbidity
from device-related infections are signiﬁcantly higher in
transvenous ICD systems.12
A general challenge for the implantation of the S-ICD is
adequate sensing through the device to avoid QRS or T-wave
oversensing, which might lead to inappropriate shocks, and
several predictors of failed sensing screening have been
identiﬁed.12,13 In the S-ICD, sensing occurs via 3 bipolar
vectors (primary, secondary, and alternate vector), which are
created between the proximal and distal lead electrode and
the S-ICD can (Figure 1C). The importance of obtaining
sensing templates during exercise testing prior to implanta-
tion has been illustrated,14 but this was not feasible in our
patient because of his limited mobility owing to foot surgery
and his comorbidities. Therefore we had to rely exclusively
on resting sensing screening. An alternative option for
sensing screening would have been mapping of the optimal
electrocardiogram vectors by the time his epicardial pace-
maker system was implanted. This could improve the like-
lihood of sensing success in patients with similar conditions.
In addition to QRS or T-wave oversensing, a concomitant
dual-chamber pacemaker exhibits the potential for over-
sensing of atrial pacing through the S-ICD, as shown in our
case (Figure 2A). This problem might be even more com-
mon in epicardial pacemaker systems because of the close
Figure 3 Deﬁbrillation threshold testing. A: Ventricular ﬁbrillation (VF) was induced with a 50 Hz train through the subcutaneous implantable cardioverter-
deﬁbrillator (S-ICD). The VF induction was not detected by the epicardial dual-chamber pacemaker and continued pacing is recorded during the VF induction.
B: Subsequently appropriate VF detection by the epicardial pacemaker. Despite several attempts, the inducible VF was self-terminating before shock delivery
through the S-ICD. RA ¼ right atrial.
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anatomic reasons epicardial leads are usually placed on the
right atrial free wall and alternative atrial lead positions are
limited. The fact that we had to implant the S-ICD lead in a
right parasternal position put the epicardial atrial leads in
proximity to the B electrode and certainly favored atrial
oversensing through the S-ICD. Adjustment of the atrial
pacing output eliminated double counting by the S-ICD in
our case, but will require frequent and careful reassessment
during follow-up. The risk of atrial oversensing might be
lower in an S-ICD system with a standard left parasternal
lead position. Another generally important issue is the
inactivation of the lead polarity switch in the pacemaker
system to avoid unipolar pacing, which might increase the
chances of double counting on the S-ICD.11
Strategies to avoid double counting of atrial and ven-
tricular pacing through the S-ICD include minimizing of the
atrial pacing output to the lowest acceptable values and
programming the trigger rate for VF detection to 42 the
upper pacing rate. In our case, we programmed the upper
pacing rate to 100 bpm and the detection rate for VF toZ220
bpm. An upper pacemaker rate of 100 bpm was thought to be
acceptable for our elderly patient with a very limited mobility
at baseline, but such a programming might not be appropriate
for younger and more active patients. Thus, even in the case
of double counting of atrial and ventricular pacing the sensed
rate through the S-ICD would still be below the VF detection
threshold and should not cause inappropriate shocks.In our case, inducible VF was correctly detected by the
epicardial pacemaker (Figure 3B), but the VF induction was
missed (Figure 3A). Continued pacing during VF might
cause VF undersensing by the S-ICD and withhold appro-
priate therapy. The rationale for this concern is the voltage
difference between paced beats and low-voltage VF (0.1-0.3
mV in our case). The role of follow-up DFT testing is as yet
undetermined.
The major limitation of our report is a limited follow-up
period, which does not allow us to draw any conclusions
concerning the long-term efﬁcacy and safety of the combi-
nation of S-ICD and permanent epicardial pacemaker in
patients with secondary prevention ICD.
Another limitation of our report is the absence of docu-
mented deﬁbrillation efﬁcacy for inducible VF at the time of
implantation. The inability to induce sustained VF was the
reason to abandon intraoperative DFT testing after multiple
unsuccessful attempts and a prolonged procedure. Never-
theless, an elective DFT testing should be considered during
his follow-up in this patient with a secondary prevention ICD
and a history of appropriate ICD shocks in the past.
At present, the combination of S-ICD with a concomitant
permanent pacemaker should be limited to highly selected
patients and the implantation should only be performed in
specialized centers. The complex interaction between S-ICD
and permanent pacemaker requires close follow-up by a
center experienced in complex device conditions in order to
address the challenging issues of device programming.
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Complex extravascular pacing and an ICD system may be
required in selected patients. We report the feasibility and
safety of co-implantation of an S-ICD and a permanent
epicardial pacemaker. Device programming is challenging
because of the complex interaction of 2 separate devices, but
this approach does seem feasible.
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